PUNE, India, November 17, 2015 /PRNewswire/ --
Ischemic Stroke - Pipeline Review, H2 2015 provides an overview of the therapeutic pipeline with an objective of enhancing decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Complete report on Ischemic Stroke Pipeline Review spread across 277 pages, analyzing 40+ companies and supported with 73 tables and 16 figures is now available at http://www.reportsnreports.com/reports/435360-ischemic-stroke-pipeline-review-h2-2015.html .
This report provides comprehensive information on the therapeutic development for Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Stroke and special features on late-stage and discontinued projects.
The report provides a snapshot of the global therapeutic landscape of Ischemic Stroke. The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities and key players involved in the therapeutics development for Ischemic Stroke and enlists all their major and minor projects summarizing all the dormant and discontinued pipeline projects. A review of the Ischemic Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages, detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Ischemic Stroke pipeline on the basis of target, MoA, route of administration and molecule type and latest news and deals relating related to pipeline products.
Order a copy of Ischemic Stroke - Pipeline Review, H2 2015 market research report at http://www.reportsnreports.com/purchase.aspx?name=435360 .
Top Companies covered in this report AB Science SA, Acticor Biotech, advanceCor GmbH, Angion Biomedica Corp., AstraZeneca Plc, Athersys, Inc., biOasis Technologies Inc., Biogen, Inc., BioTime, Inc., D-Pharm Ltd., Daiichi Sankyo Company, Limited, DiaMedica Inc., Digna Biotech, S.L., Genervon Biopharmaceuticals, LLC, Glialogix, Inc., Glucox Biotech AB, Grifols, S.A., Huons Co., Ltd., International Stem Cell Corporation, JN-International Medical Corporation, Laboratoires Pierre Fabre SA, Lumosa Therapeutics Co., Ltd., MediaPharma s.r.l., Mitsubishi Tanabe Pharma Corporation, Neuralstem, Inc., Neurotec Pharma SL, NeuroVive Pharmaceutical AB, NoNO, Inc., Panacea Pharmaceuticals, Inc., Pharmicell Co., Ltd., PhytoHealth Corporation, Remedy Pharmaceuticals, Inc., ReNeuron Group Plc, SanBio, Inc., Saneron CCEL Therapeutics, Inc., Simcere Pharmaceutical Group, Stemedica Cell Technologies, Inc., SynZyme Technologies, LLC, The International Biotechnology Center (IBC) Generium, TikoMed AB, vasopharm GmbH, Vicore Pharma AB and Virogenomics, Inc.
Drug Profiles discussed in this report are 3K3A-APC, ACT-017, alteplase biosimilar, BB-3, BSc-2118, C-21, Cerecellgram-Stroke, CNB-001, DB-017, DM-199, Drugs to Inhibit Sir2 Protein for Ischemic Stroke and Myocardial Infarction, DS-1040, GLX-1112, glyburide, GM-602, GXNPC-1, HBN-1, HU-010, Human Plasmin, Human Umbilical Cord Blood Cell Therapy for Neurological and Cardiovascular Diseases, ISC-hpNSC, levomilnacipran hydrochloride ER, LT-3001, Lysimab, masitinib, Memantine Nitrone, Mesenchymal Stem Cells, MP-124, MPHE-001A, MTfp-siRNA, MultiStem, NA-1, natalizumab, NSI-566, NTKC-005, NVP-014, NVX-208, PAN-811,Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke, PHN-014, Pinocembrin, Polyglactin 370 for Ischemic Stroke, PR-15, prasugrel hydrochloride, Protein for Ischemic Stroke, Recombinant Peptide for Ischemic Stroke, Recombinant Plasmin, Recombinant Protein for Ischemic Cerebral Stroke and Myocardial Ischemia, Recombinant Proteins to Inhibit Serine Protease for Thrombosis, Ischemic Stroke and Atherosclerosis, ReN-001, RTL-551, SB-623, SIM-071201, Small Molecule to Activate Epsilon PKC for Ischemic Stroke, Small Molecule to Block Sodium Channels for Ischemic Stroke, Small Molecule-1 to Inhibit NOX-4 for Acute Ischemic Stroke, Small Molecule-2 to Inhibit NOX-4 for Acute Ischemic Stroke, Small Molecules to Activate Glutathione Peroxidase for Ischemic Stroke and Liver Failure, Small Molecules to Block Sodium and hERG Channel for Ischemic Stroke, Small Molecules to Inhibit CaMKII for Ischemic Stroke, Small Molecules to Inhibit Kinase for Ischemic Stroke, SMTP-7, StromAb, T-33, TF-0023, THR-18, ticagrelor, TM-700, TPAi-14, TPAi-23, TS-01, TXA-127, TXA-302, UCCB-01144, Vaccine to Target NMDAR1 for Ischemic Stroke, VACNO and VAS-2870.
Explore more reports on Pharmaceuticals industry at http://www.reportsnreports.com/market-research/pharmaceuticals/ .
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
+ 1 888 391 5441